When to Start Antihypertensive Therapy in Patients with Elevated Blood Pressure
“Thank you for your thorough assessment and management plan. I agree that primary (essential) hypertension is the most likely working diagnosis given Mr. Mercer’s persistent blood pressure readings over a three-month period and the presence of multiple cardiovascular risk factors, including dyslipidemia, smoking, alcohol use, overweight status, physical inactivity, and a positive family history of hypertension. Secondary hypertension remains an important differential diagnosis; however, based on the information provided, there are no obvious clinical features currently suggesting a secondary cause. [cfp.ca] Regarding your question about when to initiate antihypertensive therapy, I can see merit to both approaches. On one hand, the 2025 Hypertension Canada guideline emphasizes confirming hypertension with home blood pressure monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM) whenever possible, as out-of-office measurements improve diagnostic accuracy and help identify white-coat hypertension. Obtaining home readings before initiating medication would provide a more accurate picture of Mr. Mercer’s baseline blood pressure and help determine whether his elevated clinic readings truly reflect sustained hypertension. On the other hand, there is also a strong argument for initiating treatment without waiting for HBPM. The 2025 Hypertension Canada guideline defines hypertension as a BP ≥130/80 mmHg and recommends pharmacologic treatment for patients whose BP remains above target despite lifestyle interventions, particularly when additional cardiovascular risk factors are present. Mr. Mercer has had repeated office blood pressure measurements averaging approximately 150/90 mmHg over three months, placing him well above the diagnostic threshold. Combined with his smoking history, dyslipidemia, excess weight, inactivity, alcohol use, and family history, these findings increase the likelihood that he has true, sustained hypertension rather than an isolated white-coat effect. In this context, delaying treatment until HBPM is completed may not necessarily change management. While home readings would certainly strengthen diagnostic certainty, the consistency of his office measurements and overall cardiovascular risk profile suggest that pharmacologic therapy will likely be required regardless of the results. Furthermore, waiting for HBPM could prolong exposure to elevated blood pressure and the cumulative risk of cardiovascular and renal complications if he does, in fact, have sustained hypertension. [cfp.ca] What makes this case challenging is that both approaches can be justified. If medication is started immediately, we lose the opportunity to assess his untreated home blood pressure and definitively evaluate for white-coat hypertension. If treatment is deferred, however, we may be delaying intervention in a patient whose repeated elevated readings and risk factors strongly support the diagnosis. Personally, I would arrange HBPM as soon as possible while implementing lifestyle modifications immediately, but I would have a very low threshold to begin antihypertensive therapy given the pattern of elevated readings and his overall cardiovascular risk burden. Overall, I think your management plan is well supported and highlights the importance of balancing guideline-directed confirmation of hypertension with clinical judgment. In a patient like Mr. Mercer, whose BP has been consistently around 150/90 mmHg over several months and who has multiple cardiovascular risk factors, I think a reasonable case could be made either for obtaining HBPM prior to treatment or for initiating therapy at this visit while continuing further assessment. It raises an interesting clinical question: at what point does the combination of persistently elevated office blood pressures and significant cardiovascular risk become sufficient to justify treatment without waiting for out-of-office confirmation?”
Summary
The 2025 Hypertension Canada guideline defines hypertension at ≥130/80 mmHg and advises starting medication for patients with high cardiovascular risk, such as multiple risk factors, even before out‑of‑office BP confirmation. It recommends home or ambulatory monitoring when possible, but does not make it a prerequisite for initiating therapy in a patient with consistent office readings around 150/90 mmHg.
Sources 60 searched
- The case for home monitoring in hypertension - PMC
This is impractical in a doctor's surgery, and the only realistic long-term strategy is to involve the patient in measuring his or her own BP in their own environment. Evidence is presented that such a strategy is better able to predict risk, is cost-effective for diagnosing hypertension, can ...
- The role of home BP monitoring: Answers to 10 common questions - PMC
A meta-analysis of 15 studies showed that therapeutic inertia was less common with HBPM than with office BP monitoring alone; the relative risk for unchanged medication was 0.82 (95% CI, 0.68 to 0.99) with HBPM.26 However, 10 of the 15 studies were of low quality with a Jadad score ≤3. Yes (SOR B). Two RCTs that looked at self-monitoring of BP and self-titration of hypertensive medications showed significant reductions in BP levels.27,28 In a cluster RCT of home BP telemonitoring, in which the pharmacist adjusted antihypertensives based on transmitted BP measurements, hypertension control was significantly better in the intervention group than in the usual care group (57.2% vs 30%).29
- The Evolution of Hypertension Management in Canada: A Review of the Current Guidelines - PMC
The new shift in the guidelines highlights lowering the threshold of treating hypertension at a blood pressure (BP) of ≤130/80 mmHg and the use of single-pill combination medication as first-line pharmacological therapy. Understanding these evolving trends is essential for clinicians and ...
- Recommendations - Guideline for the pharmacological treatment of hypertension in adults - NCBI Bookshelf
The anticipated desirable consequences of shorter follow up are better BP control and monitoring of side-effects, and perhaps improved adherence. Longer follow-up times are expected to lead to loss to follow up. A systematic review of the impact of interventions to improve medication adherence in adults prescribed antihypertensive medications suggested a decrease in adherence with an increase in time between intervention and follow up (70).
- Epidemiologic Implications of the 2025 Hypertension Canada Guideline on Hypertension Prevalence, Treatment, and Control: A Population-based Cohort Study - ScienceDirect
Treatment initiation thresholds were set at BP ≥ 160/100 mm Hg for participants at low cardiovascular risk, BP ≥ 130/80 mm Hg for those with diabetes, SBP ≥ 130 mm Hg for those at high cardiovascular risk, and BP ≥ 140/90 mm Hg for all ...
- Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review | Hypertension Research
In contrast, HBPM was recommended as the preferred initial approach for detecting the white-coat effect and masked uncontrolled hypertension among adults taking antihypertensive medication.
- Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review - PubMed
The studies reviewed consistently showed moderate diagnostic agreement between HBPM and ABPM, and superiority of HBPM compared to office measurements in diagnosing uncontrolled hypertension, assessing antihypertensive drug effects and improving ...
This fact check is free and donation-based. $1 powers ~30 fact-checks.
